ADH-503

Research use only, not for human use.

ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.

ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.

ADH-503 ((Z)-Leukadherin-1 choline; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b+ cells and subsets of CD11b+ monocytes, granulocytes, eosinophils, and macrophages.

ADH-503 ((Z)-Leukadherin-1 choline; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. ADH-503 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively. Animal Model:KPC mice [p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/flox]Dosage:30, 60, or 120 mg/kg Administration:Oral gavage; 60 days Result:Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.Animal Model:Male rats Dosage:30, 100 mg/kg (Pharmacokinetic Analysis)Administration:Oral gavage twice a day; on days 1 and 5 Result:Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively.

——

Immunology/Inflammation

Complement System

CD11b

——

——

2055362-74-6

524.7

C27H28N2O5S2

>98% (HPLC)

In Vitro:?Methanol : 100 mg/mL (190.60 )

C[N+](C)(C)CCO.[O-]C(=O)c1ccc(cc1)-c1ccc(\C=C2/SC(=S)N(Cc3ccccc3)C2=O)o1

——

(-20℃)

With Ice Pack

≥ 2 years